Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Mingming Xiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0862-2501; OpenAlex author ID A5077222614. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2024: 5 papers · 2025: 6 papers · 2026: 2 papers

Papers 13

  1. ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.09.032↗
  2. Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibi… Co-author DOI 10.1136/gutjnl-2025-336235↗
  3. m6A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Co-author DOI 10.1038/s41419-025-08049-2↗
  4. Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Co-author DOI 10.1053/j.gastro.2025.03.019↗
  5. TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality. Co-author DOI 10.1136/gutjnl-2024-332782↗
  6. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334361↗
  7. Tumor microenvironment phenotyping guides precision therapy in unresectable pancreatic cancer. First author DOI 10.4251/wjgo.v17.i10.109830↗
  8. The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. First author DOI 10.7150/thno.111180↗
  9. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. Co-author DOI 10.1016/j.redox.2024.103200↗
  10. Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. Co-author DOI 10.1038/s41416-024-02631-9↗
  11. NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy. Co-author DOI 10.1038/s41419-024-06984-0↗
  12. NLRP4 drives olaparib resistance in pancreatic cancer. Co-author DOI 10.1080/27694127.2024.2422729↗
  13. PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cells. Co-author DOI 10.1126/sciadv.adk6633↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Si Shi · 11 shared papers, 2024–2026 · strength 2.66
  2. Xianjun Yu · 8 shared papers, 2024–2026 · strength 1.80
  3. Jin Xu · 5 shared papers, 2024–2026 · strength 1.17
  4. Yalan Lei · 4 shared papers, 2024–2025 · strength 0.87
  5. Xianjun Yu · 3 shared papers, 2024–2025 · strength 0.85
  6. Xu He · 3 shared papers, 2024–2026 · strength 0.77
  7. Di Wu · 3 shared papers, 2024–2026 · strength 0.76
  8. Xuhui Tong · 3 shared papers, 2024–2025 · strength 0.70
  9. Qingcai Meng · 3 shared papers, 2024–2026 · strength 0.66
  10. Zhen Tan · 3 shared papers, 2025 · strength 0.65
  11. Xiaoqi Mao · 3 shared papers, 2024 · strength 0.63
  12. Jing Yang · 2 shared papers, 2024–2025 · strength 0.45
  13. Mingwei Dong · 2 shared papers, 2024–2026 · strength 0.44
  14. Jie Hua · 2 shared papers, 2024–2026 · strength 0.44
  15. Zeyin Rong · 2 shared papers, 2025 · strength 0.41
  16. Jin Xu · 2 shared papers, 2025 · strength 0.41
  17. Kai Zhao · 1 shared paper, 2025 · strength 0.37
  18. Xiao Xiao · 1 shared paper, 2025 · strength 0.37
  19. Jing Yang · 1 shared paper, 2025 · strength 0.28
  20. Wei Wang · 1 shared paper, 2025 · strength 0.28
  21. Daohai Qian · 1 shared paper, 2026 · strength 0.23
  22. Zhenshun Song · 1 shared paper, 2026 · strength 0.23
  23. Zhilong Ma · 1 shared paper, 2026 · strength 0.23
  24. Heng Zhu · 1 shared paper, 2025 · strength 0.22
  25. Rong Tang · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.